Lalaoui Najoua, Vaux David Lawrence
Cell Signalling and Cell Death, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 3052, Australia.
Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, 3050, Australia.
F1000Res. 2018 Dec 3;7. doi: 10.12688/f1000research.16439.1. eCollection 2018.
The inhibitor of apoptosis proteins (IAPs) are a family of proteins that were chiefly known for their ability to inhibit apoptosis by blocking caspase activation or activity. Recent research has shown that cellular IAP1 (cIAP1), cIAP2, and X-linked IAP (XIAP) also regulate signaling by receptors of the innate immune system by ubiquitylating their substrates. These IAPs thereby act at the intersection of pathways leading to cell death and inflammation. Mutation of IAP genes can impair tissue homeostasis and is linked to several human diseases. Small-molecule IAP antagonists have been developed to treat certain malignant, infectious, and inflammatory diseases. Here, we will discuss recent advances in our understanding of the functions of cIAP1, cIAP2, and XIAP; the consequences of their mutation or dysregulation; and the therapeutic potential of IAP antagonist drugs.
凋亡抑制蛋白(IAPs)是一类蛋白质,主要因其能够通过阻断半胱天冬酶的激活或活性来抑制细胞凋亡而闻名。最近的研究表明,细胞IAP1(cIAP1)、cIAP2和X连锁IAP(XIAP)还通过使其底物泛素化来调节先天免疫系统受体的信号传导。因此,这些IAPs作用于导致细胞死亡和炎症的信号通路的交叉点。IAP基因的突变会损害组织稳态,并与多种人类疾病相关。小分子IAP拮抗剂已被开发用于治疗某些恶性、感染性和炎症性疾病。在这里,我们将讨论在理解cIAP1、cIAP2和XIAP功能方面的最新进展;它们突变或失调的后果;以及IAP拮抗剂药物的治疗潜力。